CUE News and Press, Cue Biopharma Inc. From 03/13/24

2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company’s lead clinical asset, CUE-101, w...

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healt...

2024-01-09 05:05:30 ET Summary Cue Biopharma is a biotech focused on developing immunogenic peptides to fight specific diseases, particularly cancers. CUE's most advanced project, CUE-101, has shown favorable early results in a phase 1 trial for recurrent or metastatic head and ne...

2023-12-14 07:04:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cue Biopharma (NASDAQ: CUE ) just reported results for the third quarter of 2023. Cue Biopharma reported earnings per share of -24 cents. This was above the analyst estima...

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities H...

2023-11-11 15:32:08 ET Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Conference Call November 9, 2023 04:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann M...

Cue Biopharma Inc. (CUE) is expected to report $-0.3 for Q3 2023

2023-11-09 16:46:47 ET More on Cue Biopharma Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Biopharma For further details see: Cue Biopharma reports Q3 results

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023. R...